Quest Diagnostics Inc. (DGX): Price and Financial Metrics


Quest Diagnostics Inc. (DGX): $150.46

-2.15 (-1.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

DGX POWR Grades

  • Quality is the dimension where DGX ranks best; there it ranks ahead of 94.76% of US stocks.
  • The strongest trend for DGX is in Momentum, which has been heading up over the past 179 days.
  • DGX ranks lowest in Growth; there it ranks in the 9th percentile.

DGX Stock Summary

  • With a market capitalization of $16,977,204,557, QUEST DIAGNOSTICS INC has a greater market value than 88.47% of US stocks.
  • Revenue growth over the past 12 months for QUEST DIAGNOSTICS INC comes in at -6.81%, a number that bests just 15.83% of the US stocks we're tracking.
  • The volatility of QUEST DIAGNOSTICS INC's share price is greater than that of just 3.76% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to QUEST DIAGNOSTICS INC are SWK, HUBB, BEN, ACGL, and NDSN.
  • DGX's SEC filings can be seen here. And to visit QUEST DIAGNOSTICS INC's official web site, go to www.questdiagnostics.com.

DGX Valuation Summary

  • In comparison to the median Healthcare stock, DGX's price/earnings ratio is 41.43% lower, now standing at 13.5.
  • DGX's price/earnings ratio has moved down 5.2 over the prior 243 months.

Below are key valuation metrics over time for DGX.

Stock Date P/S P/B P/E EV/EBIT
DGX 2022-11-22 1.6 2.7 13.5 11.7
DGX 2022-11-21 1.6 2.7 13.5 11.7
DGX 2022-11-18 1.6 2.7 13.5 11.7
DGX 2022-11-17 1.6 2.7 13.5 11.7
DGX 2022-11-16 1.7 2.7 13.8 11.9
DGX 2022-11-15 1.6 2.7 13.6 11.8

DGX Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at 53.05%.
  • The year over year cash and equivalents growth rate now stands at -42.11%.
  • Its 4 year net cashflow from operations growth rate is now at 13.66%.
DGX's revenue has moved up $2,624,000,000 over the prior 52 months.

The table below shows DGX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 10,294 1,865 1,235
2022-06-30 10,582 1,924 1,484
2022-03-31 10,679 1,982 1,881
2021-12-31 10,788 2,233 1,995
2021-09-30 11,046 2,293 2,184
2021-06-30 11,058 2,594 2,247

DGX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DGX has a Quality Grade of B, ranking ahead of 93.32% of graded US stocks.
  • DGX's asset turnover comes in at 0.812 -- ranking 31st of 81 Healthcare stocks.
  • SSY, LH, and BIOC are the stocks whose asset turnover ratios are most correlated with DGX.

The table below shows DGX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.812 0.403 0.404
2021-06-30 0.805 0.412 0.417
2021-03-31 0.750 0.404 0.340
2020-12-31 0.709 0.385 0.277
2020-09-30 0.643 0.362 0.221
2020-06-30 0.604 0.334 0.162

DGX Price Target

For more insight on analysts targets of DGX, see our DGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $157.67 Average Broker Recommendation 1.56 (Moderate Buy)

DGX Stock Price Chart Interactive Chart >

Price chart for DGX

DGX Price/Volume Stats

Current price $150.46 52-week high $174.16
Prev. close $152.61 52-week low $120.40
Day low $148.86 Volume 1,423,200
Day high $152.06 Avg. volume 1,076,758
50-day MA $138.06 Dividend yield 1.75%
200-day MA $135.81 Market Cap 17.14B

Quest Diagnostics Inc. (DGX) Company Bio


Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United StatesPuerto RicoMexico, and Brazil.  Quest also maintains collaborative agreements with various hospitals and clinics across the globe. (Source:Wikipedia)


DGX Latest News Stream


Event/Time News Detail
Loading, please wait...

DGX Latest Social Stream


Loading social stream, please wait...

View Full DGX Social Stream

Latest DGX News From Around the Web

Below are the latest news stories about QUEST DIAGNOSTICS INC that investors may wish to consider to help them evaluate DGX as an investment opportunity.

Quest Provides No-Cost Wellness Testing to Underserved Black Community in the Bronx

Choose Healthy Life (CHL) is a sustainable, scalable, and transferable approach to addressing public health disparities and inequities in the Black community by establishing a health workforce in the Black church. CHL began with 50 churches in 5 cities and expanded last year to 120 churches in 13 states and the District of Columbia.

Yahoo | November 29, 2022

Quest Diagnostics Completes Acquisition of Outreach Lab Services Business of Summa Health

Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of select assets of LabCare Plus, the outreach laboratory services business of Summa Health, a large integrated health system. Additional financial terms were not disclosed.

Yahoo | November 28, 2022

Addressing Social Determinants of Health and Improving Access to Health Services and Resources

Addressing social determinants of health and improving access to health services and resources

Yahoo | November 22, 2022

The total return for Quest Diagnostics (NYSE:DGX) investors has risen faster than earnings growth over the last five years

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...

Yahoo | November 18, 2022

Quest Diagnostics To Plunge 16%? Here Are 5 Other Price Target Changes For Thursday

Citigroup cut Quest Diagnostics Incorporated (NYSE: DGX ) price target from $145 to $125. . Citigroup analyst Patrick Donnelly downgraded the stock from Neutral to Sell. Quest Diagnostics shares rose 0.9% to close at $149.27 on Wednesday. Deutsche Bank cut the price target on Target Corporation (NYSE: TGT ) from $183 to $144. Deutsche Bank analyst Paul Trussell downgraded the stock from Buy to Hold. Target shares fell 0.2% to $155.24 in pre-market trading. HC Wainwright & … Full story available on Benzinga.com

Benzinga | November 17, 2022

Read More 'DGX' Stories Here

DGX Price Returns

1-mo 4.76%
3-mo N/A
6-mo 10.33%
1-year -2.31%
3-year 50.52%
5-year 70.11%
YTD -11.32%
2021 47.86%
2020 14.11%
2019 31.13%
2018 -13.84%
2017 9.16%

DGX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full DGX Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8379 seconds.